Falcon Point Capital buys $10,599,746 stake in Integra Lifesciences Holdings Corp (IART)

Integra Lifesciences Holdings Corp (IART) : Falcon Point Capital scooped up 7,934 additional shares in Integra Lifesciences Holdings Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 134,293 shares of Integra Lifesciences Holdings Corp which is valued at $10,599,746.Integra Lifesciences Holdings Corp makes up approximately 1.78% of Falcon Point Capital’s portfolio.

Other Hedge Funds, Including , Strs Ohio boosted its stake in IART in the latest quarter, The investment management firm added 1,500 additional shares and now holds a total of 2,900 shares of Integra Lifesciences Holdings Corp which is valued at $228,897.Northwest Investment Counselors reduced its stake in IART by selling 8 shares or 0.19% in the most recent quarter. The Hedge Fund company now holds 4,255 shares of IART which is valued at $336,358. Integra Lifesciences Holdings Corp makes up approx 0.18% of Northwest Investment Counselors’s portfolio.Ls Investment Advisors boosted its stake in IART in the latest quarter, The investment management firm added 93 additional shares and now holds a total of 1,221 shares of Integra Lifesciences Holdings Corp which is valued at $96,520. Integra Lifesciences Holdings Corp makes up approx 0.01% of Ls Investment Advisors’s portfolio.

Integra Lifesciences Holdings Corp opened for trading at $83.16 and hit $84.8 on the upside on Friday, eventually ending the session at $84.27, with a gain of 1.57% or 1.3 points. The heightened volatility saw the trading volume jump to 4,08,705 shares. Company has a market cap of $3,136 M.

On the company’s financial health, Integra Lifesciences Holdings Corp reported $0.79 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.77. The company had revenue of $249.30 million for the quarter, compared to analysts expectations of $243.07 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.

Many Wall Street Analysts have commented on Integra Lifesciences Holdings Corp. Company shares were Reiterated by Barclays on Jul 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 84 from a previous price target of $77 .Integra Lifesciences Holdings Corp was Resumed by JP Morgan to “Overweight” on Jul 13, 2016. Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 74 from a previous price target of $70 .

Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.

Leave a Reply

Integra Lifesciences Holdings Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Integra Lifesciences Holdings Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.